# Neoleukin Therapeutics Inc. (NLTX)

Source: https://www.quantisnow.com/company/NLTX
Generated: 2026-11-17T19:30:02.644Z

- Ticker: NLTX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014
- Website: neoleukin.com

## About

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

## Latest NLTX news and filings

- 2024-02-14 23:05 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Neoleukin Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-neoleukin-therapeutics-inc-5265354)
- 2024-02-14 21:37 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-neoleukin-therapeutics-inc-amendment-5264230)
- 2024-02-14 21:26 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-neoleukin-therapeutics-inc-amendment-5263861)
- 2024-02-14 21:16 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Neoleukin Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-neoleukin-therapeutics-inc-5263540)
- 2024-02-14 20:08 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Neoleukin Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-neoleukin-therapeutics-inc-5262358)
- 2024-02-14 19:02 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Neoleukin Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-neoleukin-therapeutics-inc-5261941)
- 2024-02-14 14:19 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-neoleukin-therapeutics-inc-amendment-5260052)
- 2024-02-09 21:35 UTC [SEC Form 144] [SEC Form 144 filed by Neoleukin Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-neoleukin-therapeutics-inc-5246903)
- 2024-01-19 00:01 UTC [SEC Form 4] [SEC Form 4 filed by Woods Robert Keith](https://www.quantisnow.com/insight/sec-form-4-filed-by-woods-robert-keith-5194830)
- 2024-01-18 23:58 UTC [SEC Form 4] [SEC Form 4 filed by Palekar Rohan](https://www.quantisnow.com/insight/sec-form-4-filed-by-palekar-rohan-5194825)
- 2024-01-18 23:56 UTC [SEC Form 4] [SEC Form 4 filed by Noonberg Sarah B.](https://www.quantisnow.com/insight/sec-form-4-filed-by-noonberg-sarah-b-5194822)
- 2024-01-18 23:53 UTC [SEC Form 4] [SEC Form 4 filed by Freedland Cory S.](https://www.quantisnow.com/insight/sec-form-4-filed-by-freedland-cory-s-5194817)
- 2024-01-18 23:51 UTC [SEC Form 4] [SEC Form 4 filed by Baffi Robert](https://www.quantisnow.com/insight/sec-form-4-filed-by-baffi-robert-5194807)
- 2024-01-18 23:48 UTC [SEC Form 4] [SEC Form 4 filed by Jordan Julie](https://www.quantisnow.com/insight/sec-form-4-filed-by-jordan-julie-5194804)
- 2024-01-18 23:45 UTC [SEC Form 3] [SEC Form 3 filed by new insider Jordan Julie](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-jordan-julie-5194802)
- 2024-01-05 12:11 UTC [SEC Form 8-K] [Neoleukin Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neoleukin-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-5171840)
- 2023-12-27 21:03 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Neoleukin Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-neoleukin-therapeutics-inc-5156192)
- 2023-12-26 23:16 UTC [SEC Form 3] [New insider Cvijic Christine Mikail claimed ownership of 20,941 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-cvijic-christine-mikail-claimed-ownership-of-20941-shares-5155283)
- 2023-12-26 23:12 UTC [SEC Form 3] [New insider Mcminn Rachel claimed ownership of 1,250,359 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-mcminn-rachel-claimed-ownership-of-1250359-shares-sec-5155282)
- 2023-12-26 23:10 UTC [SEC Form 3] [SEC Form 3 filed by new insider Woods Robert Keith](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-woods-robert-keith-5155281)
- 2023-12-26 23:10 UTC [SEC Form 3] [SEC Form 3 filed by new insider Baffi Robert](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-baffi-robert-5155280)
- 2023-12-26 23:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Cobb Stuart](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-cobb-stuart-5155276)
- 2023-12-26 23:04 UTC [SEC Form 3] [SEC Form 3 filed by new insider Freedland Cory S.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-freedland-cory-s-5155270)
- 2023-12-22 21:15 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-neoleukin-therapeutics-inc-amendment-5153328)
- 2023-12-21 21:05 UTC [SEC Schedule 13D] [SEC Form SC 13D filed by Neoleukin Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13d-filed-by-neoleukin-therapeutics-inc-5151173)
- 2023-12-20 23:43 UTC [SEC Form 4] [SEC Form 4 filed by Baker Bros. Advisors Lp](https://www.quantisnow.com/insight/sec-form-4-filed-by-baker-bros-advisors-lp-5149664)
- 2023-12-20 22:24 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Neoleukin Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-neoleukin-therapeutics-inc-amendment-5149573)
- 2023-12-19 12:31 UTC [SEC Form 8-K] [Neoleukin Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Shareholder Director Nominations, Regulation FD Disclosure](https://www.quantisnow.com/insight/neoleukin-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-5144987)
- 2023-12-15 07:02 UTC [Market Chatter] [Neoleukin Therapeutics Plans For 1-For-4 Reverse Stock Split](https://www.quantisnow.com/insight/neoleukin-therapeutics-plans-for-1-for-4-reverse-stock-split-5139298)
- 2023-12-15 00:00 UTC [Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split](https://www.quantisnow.com/insight/neoleukin-therapeutics-announces-1-for-4-reverse-stock-split-5139192)
- 2023-12-06 21:24 UTC [SEC Form 425] [SEC Form 425 filed by Neoleukin Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-neoleukin-therapeutics-inc-5122792)
- 2023-12-06 21:21 UTC [SEC Form 8-K] [Neoleukin Therapeutics Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/neoleukin-therapeutics-inc-filed-sec-form-8-k-other-events-5122762)
- 2023-12-04 22:14 UTC [SEC Form 425] [SEC Form 425 filed by Neoleukin Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-neoleukin-therapeutics-inc-5117227)
- 2023-12-04 22:10 UTC [SEC Form 8-K] [Neoleukin Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neoleukin-therapeutics-inc-filed-sec-form-8-k-other-events-financial-5117205)
- 2023-11-30 21:06 UTC [SEC Form 425] [SEC Form 425 filed by Neoleukin Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-neoleukin-therapeutics-inc-5111484)
- 2023-11-14 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Neoleukin Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-neoleukin-therapeutics-inc-5082621)
- 2023-11-08 19:34 UTC [SEC Form S-4] [SEC Form S-4/A filed by Neoleukin Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-s-4a-filed-by-neoleukin-therapeutics-inc-amendment-5069757)
- 2023-10-18 20:09 UTC [SEC Form S-4] [SEC Form S-4/A filed by Neoleukin Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-s-4a-filed-by-neoleukin-therapeutics-inc-amendment-5026733)
- 2023-10-10 20:42 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Neoleukin Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-neoleukin-therapeutics-inc-amendment-5013386)
- 2023-10-10 20:22 UTC [SEC Form 4] [Baker Bros. Advisors Lp converted options into 592,650 shares (SEC Form 4)](https://www.quantisnow.com/insight/baker-bros-advisors-lp-converted-options-into-592650-shares-sec-5013211)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NLTX
- Earnings history: https://www.quantisnow.com/earnings/NLTX
- Dividend history: https://www.quantisnow.com/dividends/NLTX
- Insider transactions: https://www.quantisnow.com/insiders/NLTX
- Options chain: https://www.quantisnow.com/options/NLTX
- SEC 8-K filings only: https://www.quantisnow.com/company/NLTX/8-k
- RSS and alerts for NLTX: https://www.quantisnow.com/docs/rss-feeds.md
